Tags

Type your tag names separated by a space and hit enter

Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms.
J Sex Med. 2011 Sep; 8(9):2582-9.JS

Abstract

INTRODUCTION

Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) negatively affect quality of life. The α1-blockers are effective for LUTS suggestive of benign prostatic hypertrophy.

AIM

To analyze the effect of a uroselective α1-blocker on both voiding and sexual dysfunction in Thai men with LUTS.

METHODS

Of 488 men with LUTS who received 10 mg alfuzosin monotherapy once daily (OD) at a men's health clinic, 313 men (64%) completed 8 months of alfuzosin treatment and filled the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF)-5 questionnaires.

MAIN OUTCOME MEASURE

The relationships among the IPSS, IIEF-5 score, and select clinical characteristics were analyzed using multiple regression analysis. To identify changes from the baseline, the chi-square or Fisher's exact test was used for categorical or dichotomous variables and a paired Student's t-test was used for continuous variables.

RESULTS

The 313 men were followed up for a mean (standard deviation [SD]) of 35.6 (2.2) weeks. LUTS were categorized by IPSS as moderate in 100 patients (31.9%) and severe in 213 patients (68.1%). ED was graded according to the IIEF-5 as normal in 46 patients (14.7%), mild in 29 patients (9.3%), mild to moderate in 81 patients (25.9%), moderate in 47 patients (15.0%), and severe in 110 patients (35.1%). ED is associated with LUTS (P=0.008). After 8 months of alfuzosin treatment, the mean (SD) IPSS and IIEF-5 score significantly improved from 19.95 (6.4) to 11.13 (4.6) (P<0.001) and from 11.5 (6.9) to 14.9 (5.7) (P<0.001), respectively. However, the IIEF-5 score did not improve significantly in patients with severe LUTS as determined using the IPSS. The most common adverse event with alfuzosin treatment was mild (dizziness, 2.2%).

CONCLUSION

Treatment with 10 mg alfuzosin OD is safe and effective in improving voiding and sexual function in Thai men with LUTS and ED.

Authors+Show Affiliations

Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. sompolpermpong@gmail.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

21699664

Citation

Permpongkosol, Sompol, et al. "Treatment With a Uroselective Α1-blocker Improves Voiding and Sexual Function: a Study in Thai Men With Lower Urinary Tract Symptoms." The Journal of Sexual Medicine, vol. 8, no. 9, 2011, pp. 2582-9.
Permpongkosol S, Krilad-O-Larn S, Ratana-O-Larn K. Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms. J Sex Med. 2011;8(9):2582-9.
Permpongkosol, S., Krilad-O-Larn, S., & Ratana-O-Larn, K. (2011). Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms. The Journal of Sexual Medicine, 8(9), 2582-9. https://doi.org/10.1111/j.1743-6109.2011.02359.x
Permpongkosol S, Krilad-O-Larn S, Ratana-O-Larn K. Treatment With a Uroselective Α1-blocker Improves Voiding and Sexual Function: a Study in Thai Men With Lower Urinary Tract Symptoms. J Sex Med. 2011;8(9):2582-9. PubMed PMID: 21699664.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment with a uroselective α1-blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms. AU - Permpongkosol,Sompol, AU - Krilad-O-Larn,Santichai, AU - Ratana-O-Larn,Krisada, Y1 - 2011/06/23/ PY - 2011/6/25/entrez PY - 2011/6/28/pubmed PY - 2012/1/14/medline SP - 2582 EP - 9 JF - The journal of sexual medicine JO - J Sex Med VL - 8 IS - 9 N2 - INTRODUCTION: Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) negatively affect quality of life. The α1-blockers are effective for LUTS suggestive of benign prostatic hypertrophy. AIM: To analyze the effect of a uroselective α1-blocker on both voiding and sexual dysfunction in Thai men with LUTS. METHODS: Of 488 men with LUTS who received 10 mg alfuzosin monotherapy once daily (OD) at a men's health clinic, 313 men (64%) completed 8 months of alfuzosin treatment and filled the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF)-5 questionnaires. MAIN OUTCOME MEASURE: The relationships among the IPSS, IIEF-5 score, and select clinical characteristics were analyzed using multiple regression analysis. To identify changes from the baseline, the chi-square or Fisher's exact test was used for categorical or dichotomous variables and a paired Student's t-test was used for continuous variables. RESULTS: The 313 men were followed up for a mean (standard deviation [SD]) of 35.6 (2.2) weeks. LUTS were categorized by IPSS as moderate in 100 patients (31.9%) and severe in 213 patients (68.1%). ED was graded according to the IIEF-5 as normal in 46 patients (14.7%), mild in 29 patients (9.3%), mild to moderate in 81 patients (25.9%), moderate in 47 patients (15.0%), and severe in 110 patients (35.1%). ED is associated with LUTS (P=0.008). After 8 months of alfuzosin treatment, the mean (SD) IPSS and IIEF-5 score significantly improved from 19.95 (6.4) to 11.13 (4.6) (P<0.001) and from 11.5 (6.9) to 14.9 (5.7) (P<0.001), respectively. However, the IIEF-5 score did not improve significantly in patients with severe LUTS as determined using the IPSS. The most common adverse event with alfuzosin treatment was mild (dizziness, 2.2%). CONCLUSION: Treatment with 10 mg alfuzosin OD is safe and effective in improving voiding and sexual function in Thai men with LUTS and ED. SN - 1743-6109 UR - https://www.unboundmedicine.com/medline/citation/21699664/Treatment_with_a_uroselective_α1_blocker_improves_voiding_and_sexual_function:_a_study_in_Thai_men_with_lower_urinary_tract_symptoms_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1743-6095(15)33663-8 DB - PRIME DP - Unbound Medicine ER -